Top

Published in:

01-10-2016 | Original Article

Long Non-Coding RNA lincRNA-ROR Promotes the Progression of Colon Cancer and Holds Prognostic Value by Associating with miR-145

Authors: Peng Zhou, Lixia Sun, Danfeng Liu, Changkuo Liu, Lei Sun

Published in: Pathology & Oncology Research | Issue 4/2016

Abstract

Large intergenic non-coding RNA ribonucleic acids-ROR (lincRNA-ROR) has been reported to exert impacts on the maintenance of induced pluripotent stem cells and embryonic stem cells, and play important roles in human hepatocellular cancer. It contributes to tumorigenesis and metastasis and functions as a competing endogenous RNA (ceRNA) by sponging miR-145 in breast cancer. However, its clinical significance and prognostic value in colon cancer remain unknown. The aim of the present study was to clarify the clinicopathological role and prognostic value of lincRNA-ROR and miR-145 in colon cancer. In the present study, qRT-PCR was performed to measure the expression levels of lincRNA-ROR in colon cancer tissues and cell lines. Then, the clinicopathological significance and prognostic value of lincRNA-ROR were analyzed. LincRNA-ROR expression correlated with pT stage, pN stage, AJCC stage and vascular invasion. Knockdown of lincRNA-ROR restored the expression of miR-145, and had a significant influence on colon cancer cell proliferation, migration and invasion. Patients of the high lincRNA-ROR/low miR-145 group had significantly poorer outcomes than those of the low lincRNA-ROR/high miR-145 group. Taken together, Overexpression of lincRNA-ROR combined with depletion of miR-145 may exert crucial impact on colon cancer prognosis evaluation and treatment.

Brenner H, Kloor M, Pox CP (2014) Colorectal cancer. Lancet 383:1490–1502CrossRefPubMed

Sieqel R, Desantis C, Jemal A (2014) Colorectal cancer statistics, 2014. CA Cancer J Clin 64:104–117CrossRef

Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. (2010) Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:544–573CrossRefPubMedPubMedCentral

Jankowski JA, Odze RD (2009) Biomarkers in gastroenterology: between hope and hype comes histopathology. Am J Gastroenterol 104:1093–1096CrossRefPubMed

Modjtahedi H, Essapen S (2009) Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opporunities. Anti-Cancer Drugs 20:851–855CrossRefPubMed

Aslam MI, Taylor K, Pringle JH, Jameson JS (2009) MicroRNAs are novel biomarkers of colorectal cancer. Br J Surg 96:702–710CrossRefPubMed

Kiersem JB, Iksahl T, Lingjaerde OC, Guren T, Tveit KM, Kure EH (2014) Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol Oncol 8:59–67CrossRef

Yang F, Xue X, Bi J, Zheng L, Zhi K, Gu Y, et al. (2013) Long noncoding RNA CCAT1, which coild be activated by c-Myc, promotes the progression of gastric carcinoma. J Cancer Res Clin Oncol 139:437–445CrossRefPubMed

Zhang EB, Yin DD, Sun M, Kong R, Liu XH, You LH, et al. (2014) P53-regulated long non- coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression. Cell Death Dis 5:e1243CrossRefPubMedPubMedCentral

10.

Wu Y, Zhang L, Zhang L, Wang Y, Li H, Ren X, et al. (2015) Long non-coding RNA HOTAIR promotes tumor cell invasion and metastasis by recruiting EZH2 and repressing E-cadherin in oral squamous cell carcinoma. Int J Oncol 46:2586–2594PubMed

11.

Wang L, Cai Y, Zhao X, Jia X, Zhang J, Liu J, et al. (2015) Down-regulated long non-coding RNA H19 inhibits carcinogenesis of renal cell carcinoma. Neoplasma 62:412–418CrossRefPubMed

12.

Wapinski O, Chang HY (2011) Long noncoding RNAs and human disease. Trends Cell Biol 21:354–361CrossRefPubMed

13.

Khalil AM, Guttman M, Huarte M, Garber M, Rai A, Rivea Morales D, et al. (2009) Many human large intergenic noncoding RNAs associate with chromatin modifying complexes and affect gene expression. Proc Natl Acad Sci U S A 106:11667–11672CrossRefPubMedPubMedCentral

14.

Guttman M, Rinn JL (2012) Modular regulatory principles of large non-coding RNAs. Nature 482:339–346CrossRefPubMedPubMedCentral

15.

Wang Y, Xu Z, Jiang J, Xu C, Kang J, Xiao L, et al. (2013) Endogenous miRNA sponge lincRNA-ROR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal. Dev Cell 25:69–80CrossRefPubMed

16.

Eades G, Wolfson B, Zhang Y, Li Q, Yao Y, Zhou Q (2015) LincRNA-ROR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6. Mol Cancer Res 13:330–338CrossRefPubMed

17.

Zhou X, Gao Q, Wang J, Zhang X, Liu K, Duan Z (2014) Linc-RNA-ROR acts as a “spong” against mediation of the differentiation of endometrial cancer stem cells by microRNA-145. Gynecol Oncol 133:333–339CrossRefPubMed

18.

Iguchi T, Uchi R, Nambara S, Saito T, Komatsu H, Hirata H, et al. (2015) A long noncoding RNA, lncRNA-ATB, is involved in the progression and prognosis of colorectal cancer. Anticancer Res 35:1385–1388PubMed

19.

Xu TP, Huang MD, Xia R, Liu XX, Sun M, Yin L, et al. (2014) Decreased expression of the long non-coding RNA FENDRR is associated with poor prognosis in gastric cancer and FENDRR regulates gastric cancer cell metastasis by affecting fibronectin1 expression. J Hematol Oncol 7:63CrossRefPubMedPubMedCentral

20.

Zhang ZZ, Shen ZY, Shen YY, Zhao EH, Wang M, Wang CJ, et al. (2015) HOTAIR long noncoding RNA promotes gastric cancer metastasis through suppression of poly r(c)-binding protein (PCBP) 1. Mo Cancer Ther 14:1162–1170CrossRef

21.

Wu Y, Liu H, Shi X, Yao Y, Yang W, Song Y (2015) The long non-coding RNA HNF1A-AS1 regulates proliferation and metastasis in lung adenocarcinoma. Oncotarget 6:9160–9172CrossRefPubMedPubMedCentral

22.

Lee H, Kim C, Ku JL, Kim W, Yoon SK, Kuh HJ, et al. (2014) A long non-coding RNA snaR contributes to 5- fluorouracil resistance in human colon cancer cells. Mol Cell 37:540–546CrossRef

23.

Loewer S, Cabili MN, Guttman M, Loh YH, Thomas K, Park IH, et al. (2010) Large intergenic non-coding RNA-ROR modulates reprogramming of human induced pluripotent stem cells. Nat Genet 42:1113–1117CrossRefPubMedPubMedCentral

24.

Takahashi K, Yan IK, Koqure T, Haqa H, Patel T (2014) Exreacellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio 4:458–467CrossRefPubMedPubMedCentral

25.

Hou P, Zhao Y, Li Z, Yao R, Ma M, Gao Y, et al. (2014) LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis. Cell Death Dis 5:e1287CrossRefPubMedPubMedCentral

26.

Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP (2011) A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 146:353–358CrossRefPubMedPubMedCentral

27.

Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, et al. (2011) Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 147:344–357CrossRefPubMedPubMedCentral

28.

Yu CC, Tsai LL, Wang ML, Yu CH, Lo WL, Chang YC, et al. (2013) miR-145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res 73:3425–3440CrossRefPubMed

29.

Noh JH, Chang YG, Kim MG, Jung KH, Kim JK, Bae HJ, et al. (2013) MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer Lett 335:455–462CrossRefPubMed

30.

Zhang Y, Lin Q (2015) MicroRNA-145 inhibits migration and invasion by down-regulating FSCN1 in lung cancer. Int J Clin Exp Med 8:8794–8802PubMedPubMedCentral

31.

Qin J, Wang F, Jiang H, Xu J, Jiang Y, Wang Z (2015) MicroRNA-145 suppresses cell migration and invasion by targeting paxillin in human colorectal cancer cells. Int J Clin Exp Pathol 8:1328–1340PubMedPubMedCentral

32.

Foltran L, Maglio GD, Pella N, Ermacora P, Aprile G, Masiero E, et al. (2015) Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer. Future Oncol 11:629–640CrossRefPubMed

Title: Long Non-Coding RNA lincRNA-ROR Promotes the Progression of Colon Cancer and Holds Prognostic Value by Associating with miR-145
Authors: Peng Zhou
Lixia Sun
Danfeng Liu
Changkuo Liu
Lei Sun
Publication date: 01-10-2016
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 4/2016
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-016-0061-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2016

L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma

Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation

Diindolylmethane and Lupeol Modulates Apoptosis and Cell Proliferation in N-Butyl-N-(4-Hydroxybutyl) Nitrosamine Initiated and Dimethylarsinic Acid Promoted rat Bladder Carcinogenesis

The Prognostic Influence of BRAF Mutation and other Molecular, Clinical and Laboratory Parameters in Stage IV Colorectal Cancer

Genetic Polymorphism of SUMO-Specific Cysteine Proteases − SENP1 and SENP2 in Breast Cancer

Frameshift Mutation of MED25, a Transcription Regulator, and its Mutational Heterogeneity in Colorectal Cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer